Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose escalation trial of radiodynamic therapy with 5-ALA in recurrent glioblastoma
2024-517651-12-00Phase 2Authorised
- Sponsor
- Universität Münster
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by Universität Münster. Primary endpoints: Maximum tolerated dose (MTD) of repeat-dose 5-ALA over 4 weeks of fractionated conformal radiotherapy, Toxicological safety of repeat doses of 5-ALA and 3 more. Planned start Oct 2024; status: authorised.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-517651-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517651-12-00.